Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.
暂无分享,去创建一个
Chris Oostenbrink | Natalia Markova | Jennifer Venhorst | J. Venhorst | J. Lange | C. Kruse | C. Oostenbrink | M. V. van Dongen | N. Markova | Stephanie B. A. de Beer | N. de Bruin | Jos H M Lange | Maria J P van Dongen | Jurjen Frankena | Firas Bassissi | Natasja M W J de Bruin | Cathaline den Besten | Stephanie B A de Beer | Chris G Kruse | F. Bassissi | Cathaline den Besten | J. Frankena
[1] Mark A. Miller,et al. Why is it so difficult to simulate entropies, free energies, and their differences? , 2001, Accounts of chemical research.
[2] Thomas J. Raub,et al. In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.
[3] Paul J. Harrison,et al. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia , 2010, Molecular Psychiatry.
[4] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[5] J. Elguero,et al. 13C NMR chemical shifts of N-unsubstituted- and N-methyl-pyrazole derivatives , 1984 .
[6] György G Ferenczy,et al. Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.
[7] Paul J. Harrison,et al. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia , 2007, The European journal of neuroscience.
[8] J. Uslaner,et al. The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors , 2010, The open medicinal chemistry journal.
[9] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[10] G. Holdgate,et al. Measurements of binding thermodynamics in drug discovery. , 2005, Drug discovery today.
[11] Walter Huber,et al. A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.
[12] R. Copeland,et al. Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.
[13] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] S. Venkatraman,et al. The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[15] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[16] Wei Zheng,et al. A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase , 2006, Journal of biomolecular screening.
[17] U. Helena Danielson,et al. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. , 2009, Future medicinal chemistry.
[18] Gerhard Klebe,et al. Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.
[19] Michael Williams. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. , 2009, Biochemical pharmacology.
[20] J. Roder,et al. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia , 2010, Neuroscience & Biobehavioral Reviews.
[21] Sarah L. Huszar,et al. The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine , 2008, Journal of Pharmacology and Experimental Therapeutics.
[22] D. E. Clark. In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.
[23] Emanuele Perola,et al. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.
[24] K. Muir. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. , 2006, Current opinion in pharmacology.
[25] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[26] L. Pollegioni,et al. Characterization of human d‐amino acid oxidase , 2006, FEBS letters.
[27] Tjelvar S. G. Olsson,et al. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.
[28] P. Skolnick,et al. Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.
[29] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[30] Hugues Dolgos,et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.
[31] J. Elguero,et al. 13C NMR of pyrazoles , 1993 .
[32] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[33] Wilfred F van Gunsteren,et al. Biomolecular modeling: Goals, problems, perspectives. , 2006, Angewandte Chemie.
[34] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[35] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[36] Wilfred F. van Gunsteren,et al. An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase , 2001, J. Comput. Chem..
[37] K. Hashimoto,et al. Synthesis and biological evaluation of D-amino acid oxidase inhibitors. , 2008, Journal of medicinal chemistry.
[38] Wesley Schaal,et al. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. , 2002, Journal of medicinal chemistry.
[39] R. Panizzutti,et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia , 2007, Schizophrenia Research.
[40] Paul J. Harrison,et al. D-Amino acid oxidase activity and expression are increased in schizophrenia , 2008, Molecular Psychiatry.
[41] W. Kabsch,et al. Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.
[42] L. Cavarec,et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties , 2008, European Neuropsychopharmacology.
[43] M. Mansour,et al. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. , 2009, Journal of medicinal chemistry.
[44] J. Schlitter. Estimation of absolute and relative entropies of macromolecules using the covariance matrix , 1993 .
[45] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[46] F. Monsma,et al. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs , 2010, Expert opinion on drug discovery.
[47] Jörg Huwyler,et al. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. , 2008, European journal of medicinal chemistry.
[48] H. Berendsen,et al. Interaction Models for Water in Relation to Protein Hydration , 1981 .
[49] Denis M. Bayada,et al. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.
[50] Markus Christen,et al. The GROMOS software for biomolecular simulation: GROMOS05 , 2005, J. Comput. Chem..
[51] H. van de Waterbeemd,et al. Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.
[52] Herman Wolosker,et al. d‐Amino acids in the brain: d‐serine in neurotransmission and neurodegeneration , 2008, The FEBS journal.
[53] Robert A Copeland,et al. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety , 2010, Expert opinion on drug discovery.
[54] Yue-Cune Chang,et al. D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia , 2006, Biological Psychiatry.
[55] D. Javitt,et al. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. , 2010, Clinical schizophrenia & related psychoses.
[56] J. Coyle,et al. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.
[57] D. Swinney. The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.
[58] H. Tsuge,et al. Crystal structure of human D‐amino acid oxidase: Context‐dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si‐face of the flavin ring , 2006, Protein science : a publication of the Protein Society.
[59] P. Tonge,et al. Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.
[60] J. Elguero,et al. PACKING MODES IN EIGHT 3-ETHOXYCARBONYLPYRAZOLE DERIVATIVES. INFLUENCE OF THE SUBSTITUENTS ON THE CRYSTAL STRUCTURE AND ANNULAR TAUTOMERISM , 1999 .
[61] Daniel C. Javitt,et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.
[62] Daniel C Javitt,et al. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. , 2007, International review of neurobiology.
[63] F. Ceciliani,et al. Purification of beef kidney D-aspartate oxidase overexpressed in Escherichia coli and characterization of its redox potentials and oxidative activity towards agonists and antagonists of excitatory amino acid receptors. , 1999, Biochimica et biophysica acta.
[64] D. Erlanson. Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.
[65] M. S. Pilone,et al. D-Amino acid oxidase: new findings , 2000, Cellular and Molecular Life Sciences CMLS.
[66] G. Tsai. New Approaches to Treatment of Schizophrenia by Enhancing N -methyl- D -aspartate Neurotransmission , 2008 .
[67] Wilfred F. van Gunsteren,et al. A generalized reaction field method for molecular dynamics simulations , 1995 .
[68] S. Oliet,et al. Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine , 2009, Neuroscience.
[69] R. Dingledine,et al. Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.
[70] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[71] J. Kirkwood. Statistical Mechanics of Fluid Mixtures , 1935 .
[72] Julen Oyarzabal,et al. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. , 2009, Journal of pharmaceutical sciences.
[73] W. V. van Gunsteren,et al. Estimating entropies from molecular dynamics simulations. , 2004, The Journal of chemical physics.
[74] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[75] James Andrew McCammon,et al. Ligand-receptor interactions , 1984, Comput. Chem..
[76] G. Cruciani,et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.
[77] C. Parsons,et al. NMDA receptors as targets for drug action in neuropathic pain. , 2001, European journal of pharmacology.